For its first edition of Gene Therapy for Rare monogenic Diseases, the DIM Gene Therapy and the Imagine Institute brought together nearly 185 European participants around the challenges of clinical gene therapy.

Opened by Pr Arnold Munnich, president of the Imagine Institute and Mrs Zahia Zaidat, project manager in research at Paris Region, the main actors in gene therapy in Europe attended plenary sessions dedicated to the challenges of gene therapy and the presentation of the research projects supported by the DIM Gene Therapy. The 2 days event has been punctuated by poster sessions and the exceptional presence of Dr. Alessandra Biffi, co-director of gene therapy program at Boston Children’s cancer and blood disorders center, United States; Pr Amit Nathwani, Professor of haematology at University College of London, Pr Matthew Porteus, professor of paediatrics at Stanford Medicine.

From left to right : Mrs Zahia Zaidat, project manager in research at Paris Region ; Pr Matthew Porteus, professor of paediatrics at Stanford Medicine ; Pr. Marina Cavazanna, DIM Thérapie Génique scientific coordinator ; poster sessions.

This event was made possible thanks to the support of the Ile-de-France Paris Region, initiator of the program DIM Thérapie Génique which aims to promote the excellence and the influence of the territory and these teams on innovation.

We also thank all of our generous partners who contributed to the success of this event: Audentes Therapeutics, RegenxBio, Rocket Pharma, Spark Therapeutics, Bluebirdbio, Delphi Genetics, Vector Builder and Viralgen.

Successful bet for the DIM Gene Therapy that delighted many participants whether they are academic researchers, clinicians, big pharma companies or Biotechs. For its first successful edition, Gene Therapy for Rare monogenic Diseases has reinforced, in the light of personalized medicine, the grade of gene therapy at the heart of therapeutic innovation.